Categories: Prescription Medication
Description:
Abiraterone is an oral medication used in combination with androgen deprivation therapy (ADT) and low-dose prednisone for treating metastatic hormone-sensitive prostate cancer (mHSPC). It works by inhibiting CYP17, an enzyme involved in androgen production, thereby further suppressing testosterone beyond standard ADT.
Abiraterone has been shown in major trials (e.g., LATITUDE, STAMPEDE) to significantly improve overall survival and delay disease progression in both high- and low-volume mHSPC. It is generally well-tolerated, but potential side effects include hypertension, liver function abnormalities, fluid retention, and low potassium, which is why prednisone is co-administered. It's a preferred option for patients seeking an effective, non-chemotherapy alternative to docetaxel.
Treatment For:
AI generated Summary: Based on the provided information, there are no reviews available for the treatment 'Abiraterone' against 'Prostate Cancer, Metastatic hormone-sensitive prostate cancer'. The author has not provided a review or rating for this treatment. Therefore, it is not possible to determine the effectiveness of Abiraterone for this specific type of prostate cancer based on the given data.
The information, including but not limited to, text, graphics, images and other material contained on this website/app are for informational purposes only. No material on this site/app is intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website/app.
Copyright © 2025,Curbside and related marks are registered trademarks of Curbside Tech Inc.
